High prevalence of pain among adult HIV-infected patients at University of Gondar Hospital, Northwest Ethiopia

Abere Woretaw Azagew¹
Hiwot Kassa Woreta¹
Ambaye Dejen Tilahun²
Degefaye Zelalem Anlay³
¹Department of Medical Nursing, ²Emergency and Critical Nurse Unit, ³Community Health Unit, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia

Background: HIV/AIDS are pressing global health problems. Pain is a common symptom reported by patients living with HIV/AIDS. The exact cause of pain in HIV patients has not been thoroughly described, but it may, due to a symptom of HIV itself, result from opportunistic infections, as a side effect of antiretroviral drugs, concurrent neoplasia or other causes. In addition, pain perception of HIV-infected patients is highly variable and may vary based on cultural context and patient demographics. In Ethiopia, there is insufficient evidence on the prevalence and factors associated with HIV-related pain.

Methods: A cross-sectional study was conducted among 422 adult HIV-infected patients at Gondar University Hospital antiretroviral care clinic from March 1 to May 1, 2016. Systematic random sampling was used to select study participants. A pretested interviewer-administered questionnaire and a standardized medical record data abstraction tool were used to collect data. A short form brief pain inventory tool was used to measure the outcome. Bivariate and multivariate logistic regression models were fitted to identify factors associated with pain among adult HIV patients.

Results: The prevalence of pain was found to be 51.2% (95% CI: 46.4%–55.9%). Headache (17.9%), abdominal pain (15.6%), and backache (13.3%) were the most common symptoms of study participants. Being female (adjusted odds ratio [aOR]=1.8, 95% CI: 1.1–2.9); regular alcohol intake (aOR=3.3, 95% CI: 1.5–7.2); baseline World Health Organization clinical disease stage: II (aOR=2.5, 95% CI: 1.2–4.9), III (aOR=2, 95%, CI: 1.1–3.6), and IV (aOR=2.4, 95% CI: 1.1–5.3); and the presence of a chronic comorbid condition (aOR=5.9, 95% CI: 2.1–16.7) were significantly associated with pain.

Conclusion: Adult HIV patients in this sample reported a high level of chronic pain. Healthcare providers should better implement a routine pain assessment among HIV-positive patients to alleviate their suffering.

Keywords: human immunodeficiency virus, acquired immune deficiency syndrome, sub-saharan Africa, Ethiopia, pain, prevalence

Introduction

HIV and AIDS are among the most devastating health problems throughout the world and especially in developing countries. It is estimated that there are 36.7 million people living with HIV/AIDS and that 1.1 million die annually of AIDS-related illnesses. Sub-Saharan Africa remains one of the most severely affected regions accounting for nearly 70% of the people living with HIV worldwide.¹ In Ethiopia, the national adult HIV/AIDS prevalence has been reported to be 1.14%.² It has been estimated that 542,121
adults and 178,500 children require antiretroviral treatment in Ethiopia. In addition to the immune dysfunction resulting from HIV/AIDS infection, patients also suffer from a range of other symptoms, including pain. Pain has been defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Many people report pain in the absence of tissue damage or any pathophysiologic change”. Pain can occur across the clinical stages of HIV disease but is believed to increase in severity and intensity as HIV disease progresses. Reasons for HIV-related pain have not been fully established, but it may be a symptom of HIV disease, resulting from other illnesses or infections – including opportunistic infections – that occur as a side effect of antiretroviral drugs, concurrent neoplasia or other cause.

HIV-related chronic pain is commonly associated with peripheral receptor hypersensitization by inflammation or central sensitization in which the brain receives strong signals of pain. HIV-related pain can affect different anatomic sites. Peripheral neuropathy, headache, abdominal pain, joint pain muscle pain, bone pain and herpes-related pain are common types of HIV-related pain. Previous reports have estimated that 39%–85% of individuals with HIV infection suffer from chronic pain compared with only 20%–30% of general population. Geographic and cultural variations in reports of pain in HIV/AIDS patients have been reported. In India, the prevalence of pain was 66.7% in in-patients and 24.5% in out-patients. Pain in the sole of feet and low back pain were the common complaints next to headache. In the USA, a study among HIV-infected women showed that 27.4% had infrequent pain, 25.7% frequent pain and 20.4% highly frequent pain, while 10% reported daily pain or pain that lasted 120 days. In Nigeria, pain was reported in 83.7% of patients and in patients with pain impacted patients’ functioning, including general activity (86.7%), mood (89.9%), sleep pattern (73.4%) and work activities (83%). Other studies have shown that pain results in sleep disturbance and functional limitations. Using a standardized pain assessment, patients in Uganda reported pain as mild (53%), moderate (20%) and severe (27%).

Acute (lasting weeks or fewer weeks) or chronic pain (lasting weeks or more) can lower the quality of life and, in severe cases, profoundly disrupt the ability to engage in day-to-day activities. In HIV/AIDS patients, pain causes both short- and long-term emotional and mental health distress.

Pain has been associated with age, female sex, lower educational status, single marital status, history of smoking, lower CD4 count, longer duration of HIV infection and treatment with antiretroviral medications, including longer duration of antiretroviral treatment (ART), particularly protein inhibitor-based regimens, use of ART, advanced disease stage and the number of health comorbidities.

However, HIV/AIDS patients are heterogeneous and HIV/AIDS can occur with a variety of comorbid conditions resulting in pain.

Furthermore, the perception of pain may vary across different cultures, so there is an urgent need to describe HIV/AIDS-related pain across settings. In order to address the gap in understanding the prevalence of HIV-related pain and its associated factors in Ethiopia, the aim of this study was to evaluate the frequency and associated factors for pain in HIV/AIDS patients.

Methods

Study design and setting

A cross-sectional study was conducted to assess the prevalence of self-reported pain and associated factors of pain among adult HIV-infected patients. The study was conducted at the University of Gondar Hospital ART clinic from March 1 to May 1, 2016.

Gondar is a historic city located in Northwest Ethiopia, approximately about 750 km to the northwest of Addis Ababa. Gondar Hospital is a teaching and referral hospital that serves as the tertiary referral center for >5 million people. Started in 2005, ART services currently include 4 outpatient clinics, 1 ART drug refill service and pre-ART evaluation clinic, a comprehensive testing and counseling program as well as a dedicated pharmacy and laboratory services. More than 7500 adults and 700 pediatric HIV-infected patients have been enrolled in HIV care since services began and >5100 adult HIV-infected patients are actively followed. The clinics use international guidelines for initiation and management of ART. During the study period, these included CD4 <500 cell/mm³, World Health Organization (WHO) clinical disease stage, pregnant, laboring, delivery and lactating women and all <15 years children. HIV-infected patients who did not fulfill the eligibility criteria had a regular follow-up every 3 months through the pre-ART register.

Study participants

All HIV-positive adult patients who had been seen at least once prior to the data collection period were included. Patients who had recent surgery or trauma were excluded.
**Ethical statement**

The study was approved by the College of Medicine and Health Sciences Research and Ethical committee and the Institutional Review Board of the University of Gondar with Approval reference number of N/S 863/7/08 E.C. Verbal informed consent was obtained from participants. No personal identifying information, (names, date of birth, patient ID number) were recorded on the tool. Data collection tools and electronic databases were stored in a locked storage area on a secure server.

**Sample size and sampling technique**

The sample size was determined by using single population proportion formula through Epi Info StatCalc program with the assumption of 95% level of confidence and 5% marginal error and by taking prevalence of pain among HIV patients at Uganda 47%.13

With these assumptions, the sample size became 383. Anticipating a 10% non-response rate, the required sample size was 422. In the ART clinic, there were around 5100 adult HIV-infected patients who had regular follow-up every 2 months. k-value was determined by dividing the total number of adult HIV-infected patients to sample size (12), allocating randomly from 1 to 12 to determine the starting unit (2) then after arranging the patients based on the order of coming to the clinic, each study participant was selected every 12 interval using systematic random sampling.

**Data collection tools and procedures**

The data collection questionnaire had 4 parts collecting information on sociodemographic characteristics, personality-related characteristics, clinical and treatment factors and the short form of the brief pain inventory (BPI) tool. The BPI assesses pain prevalence, intensity and level of functional interference in HIV-positive patients. It has been shown to have good internal validity and reliability (Cronbach’s α=0.77 [pain severity] and 0.83 [pain interference]) for the pain severity and pain interference subscales, respectively.13,23

The BPI assesses pain intensity using a 0–10 numerical rating scale. Patients without pain (0 score) over the past 24 hours were categorized as “no pain”, and those with pain score (1–10) were categorized as “having pain”. Based on prior research, pain/functional interference was classified as “mild/mild interference” (numeric rating scale [NRS] 1–4), “moderate/moderate interference” (NRS 5–6) or “severe/severe interference” (NRS 7–10). The BPI tool also assesses the functional interference of pain using psychometric measures (general activity, mood, walking ability, normal work, relations with other people and enjoyment of life) and to mark the anatomic location of pain.13,23,24 The instrument was translated from English into Amharic and reverse translated into English to ensure conceptual integrity.

Data were collected by 4 trained and experienced HIV/ART-licensed nurses who received an overview of the study protocol and data collection methods. Fidelity to the data collection protocol was monitored by the supervisor who had regular meetings with the principal investigator at the end of each day of the data collection period. Interim data quality reports were monitored at least weekly by the principal investigator.

**Data processing and analysis**

Data were collected, coded, and entered into Epi Info (V. 7) and was exported to SPSS (V20; IBM, Armonk, NY, USA) for analysis. Descriptive statistics were generated, including frequency, percentage, mean, median, SD and interquartile range (IQR). Anatomic locations were coded by trained data collectors to identify the location of pain.

Binary logistic regression was used to identify factors associated with pain. For factors significant at p<0.2 in the binary logistic regression, a multivariable logistic regression model was fitted to control the possible effect of confounders. For the univariable logistic regression, crude odds ratio and 95% CIs and for the multivariable logistic regression, an adjusted odds ratio (aOR) and 95% CI were calculated. Variables having a p-value of <0.05 in the multivariate logistic regression model was considered as statistically significant and independently associated with the dependent variable. A backward stepwise regression was used as a variable selection method. Model fitness was checked by using Hosmer and Lemeshow goodness of fit test.

**Results**

**Sociodemographic characteristics of respondents**

All 422 HIV-infected patients participated in the study. More than half, 251 (59.5%), of the respondents were females. The median age of the respondents (IQR) was 37 (30–45) years. Among study participants, 182 (43.1%) were married and 373 (88.4%) were Christians. Majority (87.9%) of the respondents lived in urban and 346 (82%) were Amhara by ethnicity. One hundred eighteen (28%) of the respondents had completed their primary school. More than two-thirds (81.3%) were self-employed and 146 (34.6%) had medium income. Ten (2.4%) of the study participants smoked cigarettes. Eight (80%) of the smokers smoked for greater than 5 years. Forty-three (10.2%) drank alcohol regularly (Table 1).
Clinical and treatment-related characteristics of respondents

The median duration of a patient living with HIV since first confirmation was 74 months with an IQR of 72 months. More than half (59.2%) of the respondents had a baseline CD4 count of ≤200 cells/mm³. Nearly half of the respondents (51.4%) had WHO clinical disease stage III at the time of enrollment. Most of the respondents (92.7%) were on ART with a median (IQR) duration of 72 (70 months). Regarding the type of regimen, 129 (33%) were on zidovudine (AZT), lamivudine (3TC) and nevirapine (NVP)-based regimen (Table 2).

Prevalence of pain

A total of 216 adult HIV patients complained about pain that gave a 51.2% (46.4%–55.9%) of pain prevalence. The parts of the body commonly involved were the head 47 (17.9%) followed by the abdomen 41 (15.6%) and the back 35 (13.3%) (Table 3).

### Table 1 Sociodemographic and personal related variables of HIV-infected adult patients attending at ART care clinic, Gondar University Hospital, 2016 (n=422)

| Variables category        | Frequency (n) | %    |
|---------------------------|--------------|------|
| Sex                       | Male         | 171  | 40.5 |
|                           | Female       | 251  | 59.5 |
| Age group (years)         | 18–33        | 144  | 34.1 |
|                           | 34–49        | 214  | 50.7 |
|                           | ≥50          | 64   | 15.2 |
| Marital status            | Single       | 78   | 18.5 |
|                           | Married      | 182  | 43.1 |
|                           | Divorced     | 106  | 25.1 |
|                           | Widowed      | 56   | 13.3 |
| Religion                  | Christian    | 373  | 88.4 |
|                           | Muslim       | 49   | 11.6 |
| Residency                 | Urban        | 371  | 87.9 |
|                           | Rural        | 51   | 12.1 |
| Ethnicity                 | Amhara       | 346  | 82   |
|                           | Kimant       | 50   | 11.8 |
|                           | Tigray       | 19   | 4.5  |
|                           | Other        | 7    | 1.7  |
| Level of education        | Unable to read and write | 97 | 23 |
|                           | Informal education | 52 | 12.3 |
|                           | Primary school | 118 | 28 |
|                           | High school and above | 155 | 36.7 |
| Occupation                | Government employed | 79 | 18.7 |
|                           | Self employed | 343 | 81.3 |
| Income                    | Low income   | 140  | 33.2 |
|                           | Middle income | 146 | 34.6 |
|                           | High income  | 136  | 32.2 |
| Smoking                   | Smoker       | 10   | 2.4  |
|                           | Nonsmoker    | 412  | 97.6 |
| Number of cigarettes/day  | ≤5           | 5    | 50   |
|                           | >5           | 5    | 50   |
| Duration of smoking       | ≤5           | 2    | 20   |
|                           | >5           | 8    | 80   |
| Regular alcohol drinker   | Yes          | 43   | 10.2 |
|                           | No           | 379  | 89.8 |
| Type of alcohol use       | Beer and “areki” | 28 | 65.1 |
|                           | “Local tela” | 15   | 34.9 |
| Duration of alcohol intake| ≤5           | 19   | 44.2 |
|                           | >5           | 24   | 55.8 |

Note: “Other” at ethnicity – Oromo and Gurage. Abbreviation: ART, antiretroviral treatment.

### Table 2 Clinical and treatment-related characteristics of HIV-infected adult patients attending at ART care clinic, Gondar University Hospital, 2016 (n=422)

| Variables category           | Frequency (n) | %    |
|------------------------------|---------------|------|
| Total duration since HIV     | ≤72           | 204  | 48.3 |
| confirmed (months)           | >72           | 218  | 51.7 |
| Baseline CD4 count (cells/mm³) | ≤200       | 250  | 59.2 |
|                             | 201–499       | 155  | 36.7 |
|                             | ≥500          | 17   | 4.1  |
| CD4 count at ART initiation  | ≤200          | 226  | 57.8 |
|                             | >200          | 165  | 42.2 |
| The most recent CD4 count    | ≤200          | 91   | 21.6 |
| (cells/mm³)                  | 201–499       | 203  | 48.1 |
|                             | ≥500          | 128  | 30.3 |
| Baseline WHO clinical stage  | I             | 73   | 17.3 |
|                             | II            | 81   | 19.2 |
|                             | III           | 217  | 51.4 |
|                             | IV            | 51   | 12.1 |
| WHO clinical stage at ART    | I             | 58   | 14.8 |
|                             | II            | 80   | 20.5 |
|                             | III           | 203  | 51.9 |
|                             | IV            | 50   | 12.8 |
| Recent WHO clinical stage    | I/II          | 371  | 87.9 |
| Chronic comorbid condition   | Yes           | 25   | 5.9  |
|                             | No            | 397  | 94.1 |
| Type of chronic comorbid condition | Hypertension | 7   | 28   |
|                             | Diabetes mellitus | 5 | 20   |
|                             | Chronic kidney disease | 5 | 20   |
|                             | Glaucoma      | 3    | 12   |
|                             | Asthma        | 3    | 12   |
|                             | Epilepsy      | 2    | 8    |
| Opportunistic infection      | Yes           | 46   | 10.9 |
|                             | No            | 376  | 89.1 |
| Type of opportunistic infection | Tuberculosis | 14  | 30.4 |
|                             | Oral candidacies | 8 | 17.4 |
|                             | Skin rash     | 4    | 8.7  |
|                             | Upper respiratory infection | 5 | 10.9 |
|                             | Diarrhea      | 4    | 8.7  |
|                             | Post herpetic neuralgia | 3 | 6.5  |
|                             | Kalazar       | 3    | 6.5  |
|                             | Lymphoma      | 2    | 4.4  |
|                             | Otitis media  | 3    | 6.5  |

(Continued)
Effect of HIV-related pain on anatomic sites

Among respondents who had pain, 47 (21.8%) took analgesic of which 22 (45%) received paracetamol, 17 (38%) received diclofenac and 8 (17%) received tramadol. After the intake of these analgesics, the mean pain-relieving percentage was 54.9 ± 22.3% (SD) (Figure 1).

Factors associated with pain

In this study, the prevalence of pain among adult HIV-infected patients was found to be 51.2% (95% CI: 46.4–55.9). The common complaining symptoms were headache 17.9% followed by the abdominal pain 15.6% and backache 13.3%. Being female, alcohol intake, WHO clinical disease stages II, III and IV, and chronic comorbid conditions were significantly associated with pain (Table 5).

Discussion

In this study, the prevalence of pain among adult HIV-infected patients was found to be 51.2% (95% CI: 46.4–55.9). The common complaining symptoms were headache 17.9% followed by the abdominal pain 15.6% and backache 13.3%. Being female, alcohol intake, WHO clinical stage II and above and presence of comorbid conditions were determinants of chronic pain in HIV-infected adult patients. Age, lower CD4 count, time since diagnosis of HIV infection and receipt of protease inhibitor-based regimen or use of ART were not associated with the presence of pain in the current study. The finding of the study is in line with a study conducted in Uganda (47%), Botswana (48.7%) and San Francisco (55%).13,18,25 On the other hand, the magnitude of pain was lower compared with results of studies conducted in the USA (54%–83%), Nigeria (83.7%), San Francisco (91.2%), South Africa (74.2%) and the UK (62.8%).7,10,11,16,21 This could be due to the different instrument used for data collection, variation in data collection period and different study designs. Additionally, it might be attributed to variation in pain perception from individual to individual. To the contrary, the current prevalence is higher compared with those of studies done in South India (24.5%), Birmingham (34%), South Africa (22%) and Nigeria (27.8%).9,26–28 Possibly, this discrepancy might occur due to sociocultural, lifestyle and economic status differences of these countries.29

Sex was the determinant factor of pain among people living with HIV/AIDS. The likelihood of pain was higher among female patients compared with male counterparts (aOR = 1.8, 95% CI: 1.1–2.9). The finding is consistent with those other studies in San Francisco and South Africa.16,30 The biological differences and susceptibility to infections among women, especially in resource-poor setting, might attribute to this difference. The expression of pain also varies according to the culture and sex of the individuals.31

Table 2

| Variables category | Frequency (n) | %  |
|--------------------|--------------|----|
| ART drug use       | Yes          | 391 | 92.7 |
|                    | No           | 31  | 7.3  |
| Duration of ART use (months) | ≤70 | 193 | 49.4 |
|                    | >70          | 198 | 50.6 |
| ART regimen at initiation | D4T-3TC-NVP (1a) | 51 | 13  |
|                    | D4T-3TC-EFV (1b) | 35 | 9   |
|                    | AZT-3TC-NVP (1c) | 129 | 33 |
|                    | AZT-3TC-EFV(1d) | 42  | 10.7 |
|                    | TDF-3TC-EFV (1e) | 102 | 26.1 |
|                    | TDF-3TC-NVP (1f) | 32  | 8.2  |
| ART regimen change | Yes          | 116 | 29.7 |
|                    | No           | 275 | 70.3 |
| Current ART regimen | First line | 376 | 96.2 |
|                    | Second line  | 15  | 3.8  |
| Prophylaxis use    | Yes          | 177 | 41.9 |
|                    | No           | 245 | 58.1 |
| Type of prophylaxis use | INH | 2 | 1.1  |
|                    | CPT          | 175 | 98.9 |

Table 3

| Parts of body involved by pain | Frequency (n) | %  |
|-------------------------------|--------------|----|
| Headache                      | 47           | 21.7 |
| Abdominal pain                | 41           | 18.9 |
| Back pain                     | 35           | 16.2 |
| Chest pain                    | 30           | 13.8 |
| Joint pain                    | 21           | 9.7  |
| Neck pain                     | 16           | 7.4  |
| Thigh muscle pain             | 14           | 6.5  |
| Lip sore                      | 11           | 5    |
| Shoulder pain                 | 8            | 3.7  |
| Generalized body itching, pain| 8            | 3.7  |
| Generalized body pain         | 7            | 3.2  |
| Upper extremity pain          | 7            | 3.2  |
| Foot burning pain             | 7            | 3.2  |
| Tooth ache                    | 5            | 2.3  |
| Itching pain of eye           | 3            | 1.4  |
| Post-herpetic neuralgia       | 2            | 0.9  |

Table 2 (Continued)

Table 3

| Parts of body involved by pain | Frequency (n) | %  |
|-------------------------------|--------------|----|
| Headache                      | 47           | 21.7 |
| Abdominal pain                | 41           | 18.9 |
| Back pain                     | 35           | 16.2 |
| Chest pain                    | 30           | 13.8 |
| Joint pain                    | 21           | 9.7  |
| Neck pain                     | 16           | 7.4  |
| Thigh muscle pain             | 14           | 6.5  |
| Lip sore                      | 11           | 5    |
| Shoulder pain                 | 8            | 3.7  |
| Generalized body itching, pain| 8            | 3.7  |
| Generalized body pain         | 7            | 3.2  |
| Upper extremity pain          | 7            | 3.2  |
| Foot burning pain             | 7            | 3.2  |
| Tooth ache                    | 5            | 2.3  |
| Itching pain of eye           | 3            | 1.4  |
| Post-herpetic neuralgia       | 2            | 0.9  |

Abbreviation: ART, antiretroviral treatment; D4T; Stavudine; EFV, Efavirenz; TDF, Tenofovir; WHO, World Health Organization NVP, nevirapine; 3TC, lamivudine; AZT, zidovudine; INH, isoniazide preventive therapy; CPT, cotrimoxazole preventive therapy.

Level and functional interference of pain

The overall level of pain at its worst in the past 24 hours was 4.3, whereas the overall level of pain at its least in the past 24 hours was 2.9. Regarding the levels of pain at the time of data collection, the mean score was 3.5 (Table 4).

Respondents who had pain in the past 24 hours had different levels of functional interference. Among these, 7.1% of the respondents were severely affected in their general activities, 6.6% were moderately affected in their mood, 10.9% were moderately affected in their walking ability, 15.9% were moderately affected in their normal work, 13.1% affected in their sleep pattern and 3.3% in their enjoyment of life.

Among respondents who had pain, 47 (21.8%) took analgesic of which 22 (45%) received paracetamol, 17 (38%) received diclofenac and 8 (17%) received tramadol. After the intake of these analgesics, the mean pain-relieving percentage was 54.9 ± 22.3% (SD) (Figure 1).
In this particular study, alcohol intake was an important factor of pain. Adult HIV patients who took alcohol were nearly 3 times more likely to experience pain compared with non-alcohol users (aOR = 3.3, 95% CI: 1.5–7.2). A study conducted in Russia also came up with a similar finding. This is due to the fact that alcohol intake and HIV suppress the immune system independently and additively, which further result in different infectious diseases with different symptoms, including pain. The study also found that pain was significantly associated with WHO clinical disease stage II and above. This finding is supported by other studies done in Uganda, San Francisco and Botswana.

The presence of chronic comorbid condition might increase disease progression leading to pain. In addition to this, chronic comorbid condition and its management might result in pain. A short-term BPI tool was used but that failed to identify the types of pain (nociceptive or neuropathic pain), and further research on the type of pain and the adequacy of analgesic therapy is recommended.

## Conclusion

The prevalence of pain was found to be high. Being female, alcohol intake, the presence of chronic comorbid condition and WHO clinical stage II and above were significantly associated with pain prevalence. Hence, health-care providers should better implement a routine pain assessment to HIV-positive patients to alleviate from their suffering. For better understanding, conducting additional researches on specific causes, types, and intensity and management modalities of pain is important.

## Clinical implication

Pain is a common symptom among adult people living with HIV/AIDS, particularly in patients who had advanced WHO clinical disease stages.

Pain was not associated with CD4 count or ART therapy but was significantly associated with WHO disease classification.

Routine pain assessment must be performed in high-risk patient (like patient with history of comorbid condition and alcohol intake) to determine severity, impact of pain on functional abilities and quality of life.
Table 5 Factors associated with pain among HIV-infected adult patients attending at ART care clinic, Gondar University Hospital, 2016 (n=422)

| Variables                        | Pain | Crude OR | Adjusted OR |
|----------------------------------|------|----------|-------------|
|                                  | Yes  | No       |             |
| Sex                              |      |          |             |
| Male                             | 86   | 85       | 1.062 (0.720–1.566) | 1.785 (1.112–2.866)* |
| Female                           | 130  | 121      |             |             |
| Age group (years)                |      |          |             |
| 18–33                            | 69   | 75       | 1.030 (0.606–1.751) | 1.534 (0.837–2.81) |
| 34–49                            | 107  | 107      | 1.483 (0.823–2.672) | 1.799 (0.919–3.519) |
| ≥50                              | 40   | 24       | 0.912 (0.459–1.815) | 0.984 (0.445–2.174) |
| Marital status                   |      |          |             |
| Single                           | 38   | 40       | 1.030 (0.606–1.751) | 1.534 (0.837–2.81) |
| Married                          | 90   | 92       | 1.38 (0.733–2.160)  | 0.935 (0.452–1.936) |
| Divorced                         | 62   | 44       | 1.770 (1.028–3.046) | 1.215 (0.552–2.674) |
| Widowed                          | 26   | 30       | 0.912 (0.459–1.815) | 0.984 (0.445–2.174) |
| Address                          |      |          |             |
| Urban                            | 187  | 184      | 1.297 (0.297–2.341) | 0.917 (0.434–1.937) |
| Rural                            | 22   | 29       |             |             |
| Level of education               |      |          |             |
| Unable to read and write         | 57   | 40       | 1.44 (0.865–2.410)  | 1.039 (0.576–1.874) |
| Informal education               | 30   | 22       | 1.38 (0.733–2.160)  | 0.935 (0.452–1.936) |
| Primary school                   | 52   | 66       | 0.798 (0.493–1.291) | 0.73 (0.423–1.259) |
| High school and above            | 77   | 78       |             |             |
| Occupation                       |      |          |             |
| Government employed              | 36   | 43       |             |             |
| Self-employed                    | 180  | 163      | 1.319 (0.807–2.155) | 1.112 (0.583–2.121) |
| Alcohol intake                   |      |          |             |
| Yes                              | 30   | 13       | 2.395 (1.212–4.732) | 3.298 (1.517–7.167)* |
| No                               | 186  | 193      |             |             |
| Baseline CD4 count (cells/mm³)   |      |          |             |
| ≤200                             | 124  | 126      | 1.329 (0.858–2.059) | 1.467 (0.898–2.397) |
| 201–350                          | 68   | 52       | 8.871 (0.479–1.585) | 1.202 (0.601–2.403) |
| ≥350                             | 24   | 28       |             |             |
| The most recent CD4 count (cells/mm³) |    |          |             |
| ≤200                             | 52   | 39       | 1.770 (1.028–3.046) | 1.215 (0.552–2.674) |
| 201–499                          | 109  | 94       | 1.539 (0.986–2.403) | 1.197 (0.69–2.076) |
| ≥500                             | 55   | 73       |             |             |
| Baseline WHO clinical stage      |      |          |             |
| I                                | 26   | 47       |             |             |
| II                               | 46   | 35       | 2.376 (1.240–4.552) | 2.451 (1.228–4.891)* |
| III                              | 116  | 101      | 2.076 (1.200–3.592) | 1.996 (1.105–3.605)* |
| IV                               | 28   | 23       | 2.201 (1.060–4.569) | 2.379 (1.078–5.253)* |
| Most recent WHO clinical stage   |      |          |             |
| I/II                             | 184  | 187      |             |             |
| III/IV                           | 32   | 19       | 1.712 (0.937–3.128) | 0.828 (0.368–1.86) |
| Total duration since HIV confirmed (months) |      |          |             |
| ≤72                              | 106  | 98       |             |             |
| >72                              | 110  | 108      | 0.942 (0.643–1.38)  | 1.121 (0.688–1.828) |
| Comorbid condition               |      |          |             |
| Yes                              | 20   | 5        | 4.102 (1.510–11.145) | 5.883 (2.068–16.736)* |
| No                               | 196  | 201      |             |             |
| ART user                         |      |          |             |
| Yes                              | 200  | 191      | 0.982 (0.472–2.041) | 1.866 (0.695–5.01) |
| No                               | 16   | 15       |             |             |
| Prophylaxis use                  |      |          |             |
| Yes                              | 103  | 74       | 1.626 (1.101–2.402) | 1.519 (0.991–2.329) |
| No                               | 113  | 132      |             |             |

Note: *Statistically significant.

Abbreviations: ART, antiretroviral treatment; OR, odds ratio; WHO, World Health Organization.
Acknowledgment
The authors thank the study participants and data collectors for their collaboration during the data collection. They acknowledge Dr Timothy Landers for his review and input in the manuscript.

Author contributions
AW conceived the idea and wrote the proposal, participated in the data collection process, analyzed the data and drafted the paper. HK, DZ and AD approved the proposal with some revisions, participated in data analysis and reviewed the manuscript. All authors revised the paper critically and approved the final draft of the manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References
1. World Health Organization. [webpage on the Internet]. Global Health Observatory (GHO) dat, HIV/AIDS Available from http://www.who.int/gho/hiv/en/. Accessed October 3, 2017.
2. World Health Organization. [webpage on the Internet]. Ethiopia. Available from http://www.who.int/countries/eth/en/. Accessed October 3, 2017.
3. AIDSFree.[webpage on the Internet]. Ministry of Health. National Comprehensive HIV Care and Treatment Training for Health care Providers. Ethiopia. Available from https://aidsfree.usaid.gov/resources/ethiopia-national-guidelines-comprehensive-hiv-prevention-care-and-treatment. Accessed October 3, 2017.
4. IASP.[webpage on the Internet]. International association for the study of pain. IASP Taxonomy. Available from https://www.iasp-pain.org/Taxonomy. Accessed October 3, 2017.
5. Carr, DB. Pain in HIV is a major global health care problem. Pain in HIV is a major global healthcare problem. Available from https://www.iasp-pain.org/files/Content/ContentFolders/GlobalYearAgainstPain2/20042005RighttoPainRelief/paininhivaids.pdf.
6. The web project. [webpage on the Internet]. HIV related pain. Available from http://www.thewellproject.org/hiv-information/hiv-related-pain. Accessed October 3, 2017.
7. Parker, R, Stein DJ, Jelsma J. Pain in people living with HIV/AIDS: a systematic review. J Int AIDS Soc. 2014;17(1):18719.
8. Merlin JS. Chronic pain in patients with HIV infection: what clinicians need to know. Top Antir irr Med. 2015;23(3):120–124.
9. Nair SN Mary TR, Prathana S, Harrison P. Prevalence of pain in patients with HIV/AIDS: a cross-sectional survey in a South Indian State. Indian J Palliat Care. 2009;15(1):67–70.
10. Richardson JL, Heikes B, Karim R, Weber K, Anastos K, Young M. Experience of pain among women with advanced HIV disease. AIDS Patient Care STDS. 2014;23(7):503–511.
11. Ehrin LN, Otokwala JG. Inadequate pain relief in ambulatory patients with human immunodeficiency virus disease in Port Harcourt. HIV/AIDS (Auck). 2013;5:199–203.
12. Sandovol R, Roddye T, Giordano TP, Mitchell K, Kelley C. Pain, sleep disturbances, and functional limitations in people living with HIV/AIDS-associated distal sensory peripheral neuropathy. J Int Assoc Provid AIDS Care. 2014;13(4):328–334.
13. Namisango E, Harding R, Atuhaire L, et al. Pain among ambulatory HIV/AIDS patients: multicenter study of prevalence, intensity, associated factors, and effect. J Pain. 2012;13(7):704–713.
14. UNAIDS. Global factsheet, World AIDS day 2012. Available from http://files.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/20121120_FactSheet_Global_en.pdf.
15. Tsao JC, Soto T. Pain in persons living with HIV and comorbid psychological and substance use disorders. Clin J Pain. 2009;25(4):307–312.
16. Miaskowski C, Penko JM, Guzman D, Mattson JE, Bangsberg DR, Kushel MB. Occurrence and characteristics of chronic pain in a community-based cohort of indigent adults living with HIV infection. J Pain. 2011;12(9):1004–1016.
17. Makerere University Institutional Repository. [webpage on the Internet]. Namisango E. Prevalence of and factors associated with pain in ambulatory HIV and AIDS patients at the two teaching and referral Hospitals in Uganda. Available from http://dspace.mak.ac.ug/handle/10570/3421. Accessed October 3, 2017.
18. Aouizeret BE, Miaskowski CA, Gay C, et al. Risk factors and symptoms associated with pain in HIV-infected adults. J Assoc Nurses AIDS Care. 2010;21(2):125–133.
19. Namisango E, Harding R, Katabira ET, et al. A novel symptom cluster analysis among ambulatory HIV/AIDS patients in Uganda. AIDS Care. 2015;27(8):954–963.
20. Farrant L, Gwyther L, Dinat N, Mnoledi K, Hatta N, Harding R. Maintaining wellbeing for South Africans receiving ART: the burden of pain and symptoms is greater with longer ART exposure. S Afr Med J. 2014;104(2):119–123.
21. Lawson E, Sahin C, Perry E, et al. Is HIV painful? An epidemiologic study of the prevalence and risk factors for pain in HIV-infected patients. Clin J Pain. Epub 2016 Oct 17.
22. Krashin DL, Merrill JO, Tresco AM. Opioids in the management of HIV-related pain. Pain Physician. 2012;15(Suppl 3):157–168.
23. Parker R, Jelsma J, Stein DJ. Pain in amaXhosa women living with HIV/AIDS: translation and validation of the brief pain inventory–xhosa. J Pain Symptom Manage. 2015;51(1):126–132.
24. Cleeland CS. The M. D. Anderson Symptom Inventory User Guide. Version 1, 2009. Available from https://www.mdanderson.org/documents/Departments-and-Divisions/Symptom-Research/MDASI_userguide.pdf.
25. Martin C, Pehrsson P, Osterberg A, Sonnerborg A, Hansson P. Pain in HIV/AIDS: a cross-sectional survey in a South Indian State. J Int Assoc Physicians AIDS Care (Chic). 2010;10(1):35–39.
26. Merlin JS, Westfall AO, Raper JL, et al. Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. J Acquir Immune Defic Syndr. 2012;61(2):164–170.
27. Bhengu BR, Ncama BP, McNerney PA, et al. Symptoms experienced by HIV-infected Individuals on antiretroviral therapy in KwaZulu-Natal, South Africa. Appl Nurs Res. 2011;24(1):1–9.
28. Wahab KW, Salami AK. Pain as a symptom in patients living with HIV/AIDS seen at the outpatient clinic of a Nigerian Tertiary Hospital. J Int Assoc Physicians AIDS Care (Chic). 2010;10(1):35–39.
29. Jelly CA. Cross-Cultural Differences in Patient Perceptions and Outpatient Management of Chronic HIV/AIDS-related Pain; 2011. Duke University Libraries.
30. Norval DA. Symptoms and sites of pain experienced by AIDS patients. S Afr Med J. 2004;94(6):450–454.
31. Wright KP, Johnson JV. Evaluation of extended and continuous use of oral contraceptives. Ther Clin Risk Manag. 2008;4(5):905–911.
32. Tsui JI, Cheng DM, Coleman SM, et al. Pain is associated with risky drinking over time among HIV-infected persons in St. Petersburg, Russia. Drug Alcohol Depend. 2014;144:87–92.
33. Bagby GI, Amedee AM, Siggins RW, et al. Alcohol and HIV effects on psychological and substance use disorders. Alcohol Res. 2015;37(2):287–297.
34. Weatherburn TMP. Alcohol, AIDS and immunity. Br Med Bull. 1994;50(1):115–123.
35. Martin C, Persson P, Osterberg A, Sonnerborg A, Hansson P. Pain in ambulatory HIV-infected patients with and without intravenous drug use. Eur J Pain. 1999;3(2):157–164.
36. Weinberg JL, Kovarik, CL. The WHO clinical staging system for HIV/AIDS. AMA J Ethics. 2010;12(3):202–206.
37. Davis JA RR, Le TK, Xie J. Incidence and impact of pain conditions and comorbid illness. J Pain Res. 2011;4:331–345.
Effect of HIV-related pain on anatomic sites